For example, the aforementioned PDS-0330 and other small molecule claudin 1 inhibitors may be more effective in subtypes of colorectal cancers, such as CMS1 and CMS3, which possess lower levels of, and thus potentially more easily inhibitable, claudin 1. Here, CLDN1 is linked to colorectal cancer.